Parker-Hannifin Corp (PH) Stock News

Rosen Law Firm is reminding Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund invests in companies developing and commercializing photonics technology, which uses light instead of electricity for data transmission and processing. This is Defiance's fifth UCITS ETF since entering the European market in early 2026. The ETF is listed on LSE and Borsa Italiana with plans for Xetra listing, and carries a total expense ratio of 0.69%.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (PHOT), Europe's first photonics-focused ETF. The fund provides investment exposure to companies developing, manufacturing, and commercializing photonic technologies—optical hardware that uses light instead of electricity for data transmission. With a 0.69% total expense ratio, the ETF is listed on the London Stock Exchange and Borsa Italiana, with plans for Xetra listing. This is Defiance's fifth UCITS product since entering the European market earlier in 2026.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund provides exposure to companies developing and commercializing photonics technology for data transmission and processing. This is Defiance's fifth UCITS ETF launch in Europe this year, with the company accumulating $162.57 million in AUM across its UCITS product line. The ETF is listed on London Stock Exchange and Borsa Italiana, with Xetra listing planned.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (PHOT), Europe's first photonics-focused ETF. The fund targets companies developing, manufacturing, and commercializing photonic technologies that use light instead of electricity for data transmission and processing. This is Defiance's fifth UCITS product since entering the European market in early 2026, with the fund listed on London Stock Exchange and Borsa Italiana.

Defiance ETFs has launched the Defiance Photonics UCITS ETF (ticker: PHOT), Europe's first photonics-focused ETF. The fund provides exposure to companies involved in developing, manufacturing, and commercializing photonic technology—optical hardware that uses light instead of electricity to generate, transmit, and process data. This is Defiance's fifth UCITS ETF launch since entering the European market in early 2026, with the fund listed on London Stock Exchange and Borsa Italiana.

Bernstein Liebhard LLP has announced an investigation into whether certain directors and officers of Phreesia, Inc. breached their fiduciary duties to the company. The investigation targets shareholders who purchased shares prior to May 8, 2025. The law firm is seeking affected shareholders to discuss their legal rights and options.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment.

The article compares two healthcare ETFs: Invesco's IBBQ and State Street's XPH. IBBQ offers lower costs (0.19% expense ratio), broader diversification (253 holdings), and higher dividend yield (0.80%), making it better for long-term investors. XPH delivered stronger 1-year returns (63.90% vs 57.20%) with less volatility but charges higher fees (0.35%) and holds only 65 positions. Both funds have significantly underperformed the S&P 500 over five years, reflecting the challenges of biotech and pharmaceutical investing.

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

A securities class action lawsuit has been filed against Photronics, Inc. (NASDAQ: PLAB) on behalf of investors who purchased securities between December 10, 2025 and May 27, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors suffered significant losses when the truth was disclosed.

VanEck Pharmaceutical ETF (PPH) offers a lower expense ratio (0.36%) and higher dividend yield (2.00%), making it ideal for income-focused investors, while Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (49.90% vs 27.10%) but has higher fees (0.57%). PPH provides global exposure with better 5-year performance, while PJP focuses exclusively on U.S. stocks and benefits from sector momentum like the GLP-1 weight loss trend.

A securities class action lawsuit has been filed against Phreesia, Inc. for allegedly making false and misleading statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Investors who purchased stock between May 8, 2025 and March 30, 2026 and suffered losses exceeding $100,000 are encouraged to join the class action before the July 13, 2026 lead plaintiff deadline.

Rosen Law Firm is reminding investors in Phreesia, Inc. who purchased common stock between May 8, 2025 and March 30, 2026 of an important July 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Phreesia made false statements and concealed material negative facts regarding declining demand and reduced transparency in revenue sources, particularly in its network solutions segment. Investors who suffered losses exceeding $100,000 are encouraged to seek legal representation.

A class action lawsuit has been filed against Phreesia Inc. for allegedly misleading investors about revenue growth projections and risks in its Network Solutions segment. The company announced significantly lowered fiscal 2027 revenue guidance on March 30, 2026, causing the stock to plummet 26.6%. The deadline to file a lead plaintiff motion is July 13, 2026.

A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and overstating business strength. The lawsuit covers securities purchased between February 4, 2025 and February 2, 2026. Investors have until July 6, 2026 to apply as lead plaintiff.

Rosen Law Firm is notifying investors in Phreesia, Roblox, and Zoetis of ongoing securities class action lawsuits. Phreesia investors who purchased stock between May 8, 2025 and March 30, 2026 are reminded of the July 13, 2026 lead plaintiff deadline. The lawsuit alleges that Phreesia made false statements regarding slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding inventory management, clinical trial status, and long-term growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the July 6-13, 2026 deadlines.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against multiple companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false or misleading statements regarding inventory management, clinical trial prospects, and growth outlook respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status.

Phinia's VP and Controller Samantha Pombier sold 2,227 shares (25.1% of her direct holdings) for approximately $183,000. Despite the insider sale, analysts view the company favorably due to its dual-channel business model serving both OEMs and the aftermarket, strong Q1 2026 results with 10% revenue growth, and strategic expansion into alternative fuels. The stock trades at a forward P/E of ~11x, presenting a reasonable entry point for investors.

A class action lawsuit has been filed against Phreesia Inc. for allegedly misleading investors about revenue growth projections and risks in its Network Solutions segment. The company announced significantly lowered fiscal 2027 revenue guidance on March 30, 2026, causing the stock to plummet 26.6%. Investors who purchased shares between May 8, 2025 and March 30, 2026 can file a lead plaintiff motion by July 13, 2026.

The Gross Law Firm has announced a securities class action lawsuit against Phreesia, Inc. (PHR) on behalf of shareholders who purchased shares between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia made materially false and misleading statements while concealing adverse facts about slowing demand and weakened pharmaceutical marketing commitments. Following the company's announcement of significantly reduced revenue guidance on March 30, 2026, PHR stock declined approximately 27% from $11.41 to $8.38 per share. The deadline to seek lead plaintiff status is July 13, 2026.

Rosen Law Firm reminds Phreesia, Inc. (NYSE: PHR) investors of the July 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Phreesia made false or misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment, causing investor damages.

LA21-CDC received grant support from Truist Foundation to expand its Small Business Sustainability Initiative, which provides Philadelphia entrepreneurs with coaching, business systems training, capital readiness support, and AI-powered business tools to strengthen operations and build long-term sustainability.

Rosen Law Firm reminds Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.

A federal securities class action has been filed against Phreesia, Inc. (NYSE: PHR) alleging that the company and its executives made false and misleading statements about growth opportunities while concealing slowing demand and weakening pharmaceutical marketing commitments. After Phreesia announced significantly reduced revenue guidance on March 30, 2026, the stock price fell approximately 27% from $11.41 to $8.38 per share. Investors who purchased PHR stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to seek lead plaintiff appointment.

Rosen Law Firm is notifying Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of an important July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.

Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against three companies. Phreesia faces allegations of false statements regarding long-term growth outlook (deadline July 13, 2026). AeroVironment is accused of misrepresenting its competitive landscape (deadline July 27, 2026). Lucid Group faces claims about false statements regarding manufacturing and delivery capabilities (deadline July 28, 2026). Investors who purchased shares during the alleged fraud periods and suffered losses are encouraged to contact the firm.

Creative Medical Technology Holdings (NASDAQ: CELZ) announced the advancement of Project PHOENIX into a nationwide virtual data collection phase targeting at least 1,000 U.S. veterans exposed to burn pits and toxic hazards. The AI-driven platform leverages mobile-app technology and field-capable logistics to collect exposure history, health data, and multi-omics profiling. The company is developing the CELZ-Biodefense Toxic Exposure Atlas to identify biomarkers and therapeutic targets while maintaining capital efficiency through existing infrastructure.

A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) in the U.S. District Court for the District of Delaware, alleging that the company and its executives made false or misleading statements regarding revenue visibility. The company significantly reduced its FY 2027 revenue guidance from $545-$559 million to $510-$520 million on March 30, 2026, citing weaker pharmaceutical-marketing commitments and reduced visibility in its Network Solutions segment—risks that were not disclosed during the December 8, 2025 earnings call. The stock fell 21-28% following the revised outlook.